DSIR Recognized | FWA Approved - FWA00012971

Why is this research being conducted?

This study is being conducted to determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India & to devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.

Who is conducting this research?

woman

Principal Investigator

Dr Manju Mamtani, MD

Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA.

Email: manju.mamtani@utrgv.edu

man

Co-Principal Investigator

Dr Hemant Kurkarni, MD

Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA

USA Phone: +1 (210) 602-5537

Email: hemant.kulkarni@utrgv.edu

woman

Co-Investigator

Dr Archana Patel

Lata Medical Research Foundation, Nagpur, India

woman

Co-Investigator

Dr Vaishali Khedikar

Lata Medical Research Foundation, Nagpur, India

woman

Co-Investigator

Dr Seema Parvekar

Medical Superintendent, Daga Memorial Women’s Hospital, Nagpur, India.

We will test the following two hypotheses in the proposed study:

  1. Early detection of GD before 20 weeks of gestation using combinations of current and novel biomarkers will improve risk-stratification and prediction of pregnancy outcomes.
  1. The prevalence of GD in urban, central India is comparable to the national average in India.

We propose this study – Markers for Early Risk-stratification of Gestational Diabetes (MERGD) Study – with the following objectives:

PRIMARY OBJECTIVES

  1. To determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India; and
  2. To devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.

SECONDARY OBJECTIVES

  1. To estimate the prevalence of gestational diabetes in central India;
  2. To determine the biomarker-based incremental prediction of maternal and fetal outcomes over and beyond that based on clinical risk factors.
+
MERGD Home

Why is this research being conducted?

This study is being conducted to determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India & to devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.

+
Team

Who is conducting this research?

woman

Principal Investigator

Dr Manju Mamtani, MD

Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA.

Email: manju.mamtani@utrgv.edu

man

Co-Principal Investigator

Dr Hemant Kurkarni, MD

Trustee, Lata Medical Research Foundation, Nagpur, India and General Manager, M&H Research, LLC, San Antonio, TX, USA

USA Phone: +1 (210) 602-5537

Email: hemant.kulkarni@utrgv.edu

woman

Co-Investigator

Dr Archana Patel

Lata Medical Research Foundation, Nagpur, India

woman

Co-Investigator

Dr Vaishali Khedikar

Lata Medical Research Foundation, Nagpur, India

woman

Co-Investigator

Dr Seema Parvekar

Medical Superintendent, Daga Memorial Women’s Hospital, Nagpur, India.

+
Hypothesis

We will test the following two hypotheses in the proposed study:

  1. Early detection of GD before 20 weeks of gestation using combinations of current and novel biomarkers will improve risk-stratification and prediction of pregnancy outcomes.
  1. The prevalence of GD in urban, central India is comparable to the national average in India.
+
Status

We propose this study – Markers for Early Risk-stratification of Gestational Diabetes (MERGD) Study – with the following objectives:

PRIMARY OBJECTIVES

  1. To determine the incremental value of serum and plasma biomarkers in early detection of gestational diabetes in India; and
  2. To devise a risk-stratification strategy based on biomarker profile for early identification of high-risk pregnancies.

SECONDARY OBJECTIVES

  1. To estimate the prevalence of gestational diabetes in central India;
  2. To determine the biomarker-based incremental prediction of maternal and fetal outcomes over and beyond that based on clinical risk factors.
+
Gallery